2 APR 9 4/2002

830002-2003.1

Applicant'

U.S. Serial No.:

Filing Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Sadelain et al

No.: 09/872,832

06/01/01 Artificial Antigen Presenting Cells And Methods Of Use Thereof

Examiner

Date of Deposit:

To be Assigned

745 Fifth Avenue, New York, NY 10151 Express Mail

Mailing Label Number:

EL 742694537 US

October 25, 2001

I certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231

Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

COPY OF PAPERS ORIGINALLY FILED

TRANSMITTAL

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed are:

- 1) Return-receipt postcard;
- Information Disclosure Statement; 2)
- Completed Form PTO-1449; and 3)
- Copies of the cited documents. 4)

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicant

Susan K. Lehnhardt Reg. No. 33,943

(212) 588-0800



COPY OF PAPERS ORIGINALLY FILED

PATENT TECH CENTER 1600/2900 511169-2007 MSK877 09/590,247

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Sadelain et al

U.S. Serial No.:

09/872,832

Filing Date

06/01/01

For

1,

Artificial Antigen Presenting Cells And Methods Of Use Thereof

Examiner

To be Assigned

745 Fifth Avenue, New York, NY 10151

Mailing Label Number:

EL 742694537 US

Express Mail

Date of Deposit:

October 25, 2001

I certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231

Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Examiner's attention is respectfully directed to the accompanying documents listed in the accompanying Form PTO-1449. The Examiner is respectfully requested to consider, and make of record, these documents. This Information Disclosure Statement is <u>not</u> a representation that any of the cited documents are considered pertinent, or that any of the cited documents are indeed prior art.

PATENT 511169-2007 MSK877 09/590,247

This Information Disclosure Statement is being filed before the first Office Action; no fee is believed. Please charge any fee required, or credit any overpayment therein, to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

Susan K. Lehnhardt

Reg. No. 33,943



COPY OF PAPERS ORIGINALLY FILED

ROYCE, OF CALLEY

830002-2003.1 MSK877 09/872,832 Sheet 1 of 4

	TAMP	A RATE				Com	ر م	1	09/87	2
Based on Form PTO-1449				. DOCKET NO.:	- Z	10000	SERIAL 09/872			
LIST OF REFERENCES CITED BY APPLICANT					APPL	ICANT:	07.072			
			FILING DATE: June 1, 01			GROUP ART UNIT 1653			_	
EXAMINER INITIAL	-	DOCUMEN NUMBER	NT	DATE	NAME		CLASS	SUB- CLASS	FILING	_
	AA					-		CLASS	DATE	_
	AB									
	AC		-							_
	AD		+							_
	AE		-							
1	AF		+-			-				_
										_

		FOI	REIGN PAT	TENT DOCUM	ENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRAN N	NSLATIO
,	AG ,	WO 96/27392	09/12/96	WIPO			YES	NO
	AH '	WO 93/07286	04/15/93	WIPO				
	AI							
	AJ							

EXAMINER	
	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with pert community.	
not considered. Include copy of this form with next common not citation is in conformat	nce with MPED 600 D

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS ORIGINALLY FILED

DEC 2 8 2001

830002-2003.1 MSK877 09/872,832 Sheet 2 of 4

TECH CENTER 1600/2900

	(A)	THER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	neet
AK ·		Banchereau et al. (1998) "Dendritic cells and the	
	AL	Banchereau et al. (1998) "Dendritic cells and the control of immunity" Nature 392:24 Bednarek et al. (1991) "The minimum peptide epitope from the influenza virus matrix protein" J. Immunol. 147:4047–4053	5–2:
	AM		erativ
	AN	Brenner et al. (1998) "Gene and cell transfer for specific immunotherapy" Vox Sang. 7 (Suppl. 2):87–90	4
	AO	Bryant et al. (1992) "Calculation of lytic units for the expression of cell-mediated cytotoxicity" J. Immunol. Met. 146:91–103	
	AQ ,	Chen et al. (1996) "Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas" Proc. Natl. Acad. Sci. USA	
	AR .	Davis et al. (1993) "Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes" Curr. Opin. Immunol. 5:45-49	 .
	AS v	Deeths et al (1999) "ICAM-1 and B7-1 provide similar but distinct costimulation for CD T cells, while CD4+ T cells are poorly costimulated by ICAM-1" Fig. 1.1.	8+ 52
	AT '	650 Costimulation: building an immunological synapse" Science 283:64	9 <u>–</u>
A	, U.	Gallardo et al. (1997) "The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes" Gene Ther. 4:1115–1119	S
A	V,	Gong et al. (1999) "Cancer patient T cells genetically targeted to prostate-specific membra antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen" Neoplasia 1:123–127	ne
AV	V I	Kawakami et al. (1994) "Identification of the immunodominant peptides of the MART-1 numan melanoma antigen recognized by the majority of HLA-A2-restricted tumor nfiltrating lymphocytes" J. Exp. Med. 180:347–352	
AX	K	Tawakami et al. (1997) "Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy" Int. Rev. Immunol. 14:173–192	0
AMINER			

EXA	MINI	ER
-----	------	----

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

DEC 2 8 2001

830002-2003.1 MSK877 09/872,832 Sheet 3 of 4

TECH CENTER 1600/2900

T UC	(1 200 E)		DEC 2 8 2001	MSI
	1 2 5 ZMT		.TECH CENTER 1600/2900	09/872
	Le Doua studied i	arin et al. (1973) "Origin and in interspecific combinations	renewal of lymphocytes in avian eml "Nature New Biol. 246:25-27	Sheet 3
1	AZ Lehner e		2101. 240.25-27	
E	BA Levine et	t al (1007) "For	costimulation on long-term proliferate cells" J. Immunol. 159:5921–5930	tion of CD4+ T
В	B Mellman e Biol. 8:23	et al. (1998) "Antigen proces 31-237	ssing for amateurs and professionals"	Trends Cell
В	C Morrison 6	et al (1002) (11	of the nonamer peptide from influenza -A2 in its recognition by cytotoxic T	
BI	O'Reilly et	tal (1009) "A +	notherapy for Epstein-Barr virus-associting marrow allografts" Springer Sem	
BE	Ory et al. (1 retrovirus/v. 11406	1996) "A stable human-derivo vesicular stomatitis virus G ps	red packaging cell line for production seudotypes" Proc. Natl. Acad. Sci. US	of high titer SA 93:11400-
BF	Parkhurst et	t al (1006) "T	tion of melanoma-reactive CTL with part HLA-A*0201-binding residues" J. In	
BG			LFA-3 in costimulation of CD8+ T co	
ВН			tive T cell therapy of human viral disc	
BI	Riviere and S	Sadelain In Co	otocols (ed. Robbins) pp. 59–78 (Hum ruction of retroviral vectors and the ge	
BJ _v	Riviere et al. (deaminase in r	(1905) "Egg. 4 6	vector design on expression of human	

EXAMINER		
	DATE CONSIDERED	
* EXAMINER: Initial if reference considered, whether or not citation is in conformal		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and



COPY OF PAPERS ORIGINALLY FILED RECEIVED

DEC 2 8 2001

830002-2003.1 MSK877 09/872,832 Sheet 4 of 4

	DEC 2 8 2001
B	K Red deriver at (1000 (F): 11 Sheet
	antigens MART-1 and Glycoprotein-100 by HLA-A2 subtypes" I Immund 1200
BI	Rooney et al. (1998) "EBV specific CTL: A Model For Immune Therapy" Vox Sang. 74
BM	
ВО	Schultze et al. (1997) "CD40-activated human B cells: an alternative source of line of the second se
BQ	J. Clin. Invest. 100:2757-2765
BR .	Spagnoli et al. (1995) "Peptide-specific CTL in tumor-infiltrating lymphocytes from an unselected group of HLA-A2.1-positive patients" Int. J. Cancer 64:309–315
BS	Sprent et al. (1997) "Constructing artificial antigen-presenting cells from Drosophila cells" Adv. Exp. I
BT ,	Sprent (1995) "Professionals and amateurs" Curr. Biol. 5:1095–1097
BU	Timmerman et al. (1999) "Dendritic cell vaccines for cancer immunotherapy" Annu. Rev.
BV	Watts et al. (1999) "T cell co-stimulatory molecules other than CD28" Curr. Opin. Immunol. 11:286–293
BW .	Young et al. (1990) "Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells" J. Exp. Med. 171:1315–1332
	J. EXP. Med. 171:1315 1222

EXAMINER	
----------	--

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PØST OFFICE 10 TO ADDRESSEE 2nd Day 3rd Day WAIVER OF SIGNATURE (Domestic Only): Addition of signature is requested. I wish delivery to be made wit addressee's agent (if delivery employee judges that article addressee's agent (if delivery employee judges that article and the most approximate until a most in the control of the control NO DELIVERY Express Mad Corporate Accr oderal Agency Acct. No. or Instal Service Acct. No. FROM: (PLEASE PRINT) PHONE 212 588 0800 Shil y no TO: (PLEASE PRINT) FROMMER LAWRENCE & HAUG LLP 745 5TH AVE FL 10 NY 10151 NY 10151-1000 Workington D. (-2013). 830002-2009.1

> 372 1832 File No. \$30002-2003-1 Serial No. 09 Title In the Matter of the Application of Axhacul Anhan Presenting (elli & Mehin) The following due ____ in the U.S. Patent Office, was received in the Patent Office >> US ? ☐ Declaration ☐ Affidavit Express Mail Mailing Certificate ☐ Ameadment (separate sheet) Proliminary Amendment ☐ Check No_ - nendment After Final Rejection Deposit Account Order Form dequest for Extension of Time Drawing ____ Sheet(s) Tovisional Patent Application Information Disclosure Statement Application for Patent, including PTO Form 1449 Pages Specification ___ Claims Issue Fee Transmittal ☐ Declaration ☐ Oath ☐ Power ☐ Brief ☐ Letter Request for Filing Continuation or Divisional Application for TM Registration Application ____ sheets, in duplicate Including __ - Specimens File Wrapper Continuation Patent Application Status Request | Notice of Appeal sheets, in duplicate Petition ☐ Response ☐ PCT Request _____ sheets, including Priority Document Transmittal Letter to the US/RO ☐ Small Entity Declaration ☐ Assignment ☐ Recordation Cover Sheet Deheman (igh)

www.usps.com

1031/

COPY OF PAPERS ORIGINALLY FILED

PRESS HARD.

You are making 3 copies. FOR PICKUP OR TRACKING CALL 1-800-222-1811